Document is current
Any future updates will be listed below
-
Authors
Guo, Wen-Hao
Qi, Xiaoli
Yu, Xin
Liu, Yang
Chung, Chan-I
Bai, Fang
Lin, Xingcheng
Lu, Dong
Wang, Lingfei
Chen, Jianwei
Su, Lynn Hsiao
Nomie, Krystle J.
Li, Feng https://orcid.org/0000-0002-9680-4614
Wang, Meng C. https://orcid.org/0000-0002-5898-6007
Shu, Xiaokun https://orcid.org/0000-0001-9248-7095
Onuchic, José N.
Woyach, Jennifer A.
Wang, Michael L. https://orcid.org/0000-0001-9748-5486
Wang, Jin https://orcid.org/0000-0003-3625-7919
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA250503, P30-CA030199)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01-GM115622)
Howard Hughes Medical Institute
Welch Foundation (C-1792)
National Science Foundation (CHE-1614101)
Cancer Prevention and Research Institute of Texas
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 29 January 2020
Accepted: 28 July 2020
First Online: 26 August 2020
Competing interests
: J.W., W.G., X.Q., M.L.W., K.N., and Y.L. are the co-inventors of a patent related to this work. J.W. is the co-founder of CoActigon Inc. and Chemical Biology Probes LLC. X.S. and C.-I.C. have filed a patent application covering the SPPIER assay. M.L.W. receives research grants from Janssen, Pharmacyclics, AstraZeneca, Acerta Pharma, Celgene, Juno Therapeutics, BeiGene, Kite Pharma, Loxo Oncology, VelosBio, BioInvent, Aviara, Verastem, and InnoCare, consults and/or serves on the advisory board for Consulting/Advisory Board for Loxo Oncology, Janssen, Pharmacyclics, BioInvent, Celgene, Juno Therapeutics, Pulse Biosciences, MoreHealth, Guidepoint Global, Kite Pharma, AstraZeneca, Acerta Pharma, and InnoCare, received honoraria from Janssen, Acerta Pharma, OMI, Physicians Education Resources (PER), Oncology News, and Targeted Oncology, and owns stocks from MoreHealth. J.A.W. consults for Janssen, Pharmacyclics, Abbvie, AstraZeneca, and Arqule, receives research funding from Loxo Oncology and Abbvie and clinical trial funding from Pharmacyclics, Janssen, Verastem, Karyopharm, and Morphosys.
